Day 2 Recap: 2025 Revolutionizing Atopic Dermatitis Conference

Author(s):

Kaitlyn Bader, Assistant Managing Editor

Key Takeaways

Dupilumab significantly improves daily functioning, mental health, and social aspects in patients with moderate to severe atopic dermatitis.
Shared inflammatory mechanisms between atopic dermatitis and alopecia areata were emphasized, highlighting the need for clinician awareness.
JAK inhibitors' safety and recent label updates were discussed, addressing misconceptions and clinical relevance.
Lebrikizumab and upadacitinib showed promising efficacy in diverse patient populations, including those with skin of color and different biologic histories.

Catch up on coverage from the final day of the 2025 Revolutionizing Atopic Dermatitis Conference held in Nashville, Tennessee.

To stay informed with the latest conference insights, subscribe to receive our eNewsletters.

Dupilumab Significantly Enhances Quality of Life and Reduces Cumulative Impairment in Patients with Moderate to Severe Atopic Dermatitis

Data presented at the 2025 RAD Conference shows dupilumab improves daily functioning, mental health, and social aspects in patients with atopic dermatitis.

Addressing Overlapping Pathophysiology and Patient Burden in Atopic Dermatitis and Alopecia Areata

At RAD 2025, Tiffany Mayo, MD, emphasized the need for clinicians to recognize shared inflammatory mechanisms between AD and AA.

Q&A: Reframing JAK Inhibitor Safety and Flexibility in AD With Leon Kircik, MD

At the 2025 Revolutionizing Atopic Dermatitis Conference, Leon Kircik, MD, highlighted the safety of JAK inhibitors, clarified misconceptions around boxed warnings, and discussed the clinical relevance of recent label updates for abrocitinib.

Clarifying Allergy Controversies in Pediatric Atopic Dermatitis

At RAD 2025, pediatric dermatologist Lisa Swanson, MD, and allergist Anne Marie Singh, MD, led a dual session aimed at demystifying the connection between food allergy and atopic dermatitis.

Late Breaking Data: Lebrikizumab Demonstrates Efficacy in AD Patients with Skin of Color

Eli Lilly revealed promising results for lebrikizumab in treating atopic dermatitis in patients with skin of color at the RAD 2025 conference.

Late-Breaking Data: Real-World Registry Data Supports Upadacitinib Efficacy in Moderate to Severe AD, Regardless of Biologic History

At RAD 2025, Christopher Bunick, MD, PhD, presented 6-month data from the CorEvitas AD Registry, highlighting clinically meaningful skin clearance, itch reduction, and more in bio-naïve and bio-experienced adults treated with upadacitinib.

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe Now!